Personalized Therapy of Hypertension: the Past and the Future

Paolo Manunta, Mara Ferrandi, Daniele Cusi, Patrizia Ferrari, Jan Staessen, Giuseppe Bianchi

Research output: Contribution to journalArticle

Abstract

During the past 20 years, the studies on genetics or pharmacogenomics of primary hypertension provided interesting results supporting the role of genetics, but no actionable finding ready to be translated into personalized medicine. Two types of approaches have been applied: a “hypothesis-driven” approach on the candidate genes, coding for proteins involved in the biochemical machinery underlying the regulation of BP, and an “unbiased hypothesis-free” approach with GWAS, based on the randomness principles of frequentist statistics. During the past 10–15 years, the application of the latter has overtaken the application of the former leading to an enlargement of the number of previously unknown candidate loci or genes but without any actionable result for the therapy of hypertension. In the present review, we summarize the results of our hypothesis-driven approach based on studies carried out in rats with genetic hypertension and in humans with essential hypertension at the pre-hypertensive and early hypertensive stages. These studies led to the identification of mutant adducin and endogenous ouabain as candidate genetic-molecular mechanisms in both species. Rostafuroxin has been developed for its ability to selectively correct Na+ pump abnormalities sustained by the two abovementioned mechanisms and to selectively reduce BP in rats and in humans carrying the gene variants underlying the mutant adducin and endogenous ouabain (EO) effects. A clinical trial is ongoing to substantiate these findings. Future studies should apply both the candidate gene and GWAS approaches to fully exploit the potential of genetics in optimizing the personalized therapy.

Original languageEnglish
Article number24
Pages (from-to)1-11
Number of pages11
JournalCurrent Hypertension Reports
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Genome-Wide Association Study
Ouabain
Hypertension
Genes
Precision Medicine
Pharmacogenetics
Molecular Biology
Therapeutics
Clinical Trials
Proteins
adducin
rostafuroxin
Essential Hypertension

Keywords

  • Adducin
  • Candidate gene
  • Endogenous ouabain
  • Genetics
  • GWAS
  • Hypertension
  • Kidney cross-transplantation
  • Personalized therapy
  • Pharmacogenomics
  • Rostafuroxin

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Manunta, P., Ferrandi, M., Cusi, D., Ferrari, P., Staessen, J., & Bianchi, G. (2016). Personalized Therapy of Hypertension: the Past and the Future. Current Hypertension Reports, 18(3), 1-11. [24]. https://doi.org/10.1007/s11906-016-0632-y

Personalized Therapy of Hypertension : the Past and the Future. / Manunta, Paolo; Ferrandi, Mara; Cusi, Daniele; Ferrari, Patrizia; Staessen, Jan; Bianchi, Giuseppe.

In: Current Hypertension Reports, Vol. 18, No. 3, 24, 01.03.2016, p. 1-11.

Research output: Contribution to journalArticle

Manunta, P, Ferrandi, M, Cusi, D, Ferrari, P, Staessen, J & Bianchi, G 2016, 'Personalized Therapy of Hypertension: the Past and the Future', Current Hypertension Reports, vol. 18, no. 3, 24, pp. 1-11. https://doi.org/10.1007/s11906-016-0632-y
Manunta, Paolo ; Ferrandi, Mara ; Cusi, Daniele ; Ferrari, Patrizia ; Staessen, Jan ; Bianchi, Giuseppe. / Personalized Therapy of Hypertension : the Past and the Future. In: Current Hypertension Reports. 2016 ; Vol. 18, No. 3. pp. 1-11.
@article{2595fa0bcdc94314af9bacf5acf676c6,
title = "Personalized Therapy of Hypertension: the Past and the Future",
abstract = "During the past 20 years, the studies on genetics or pharmacogenomics of primary hypertension provided interesting results supporting the role of genetics, but no actionable finding ready to be translated into personalized medicine. Two types of approaches have been applied: a “hypothesis-driven” approach on the candidate genes, coding for proteins involved in the biochemical machinery underlying the regulation of BP, and an “unbiased hypothesis-free” approach with GWAS, based on the randomness principles of frequentist statistics. During the past 10–15 years, the application of the latter has overtaken the application of the former leading to an enlargement of the number of previously unknown candidate loci or genes but without any actionable result for the therapy of hypertension. In the present review, we summarize the results of our hypothesis-driven approach based on studies carried out in rats with genetic hypertension and in humans with essential hypertension at the pre-hypertensive and early hypertensive stages. These studies led to the identification of mutant adducin and endogenous ouabain as candidate genetic-molecular mechanisms in both species. Rostafuroxin has been developed for its ability to selectively correct Na+ pump abnormalities sustained by the two abovementioned mechanisms and to selectively reduce BP in rats and in humans carrying the gene variants underlying the mutant adducin and endogenous ouabain (EO) effects. A clinical trial is ongoing to substantiate these findings. Future studies should apply both the candidate gene and GWAS approaches to fully exploit the potential of genetics in optimizing the personalized therapy.",
keywords = "Adducin, Candidate gene, Endogenous ouabain, Genetics, GWAS, Hypertension, Kidney cross-transplantation, Personalized therapy, Pharmacogenomics, Rostafuroxin",
author = "Paolo Manunta and Mara Ferrandi and Daniele Cusi and Patrizia Ferrari and Jan Staessen and Giuseppe Bianchi",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s11906-016-0632-y",
language = "English",
volume = "18",
pages = "1--11",
journal = "Current Hypertension Reports",
issn = "1522-6417",
publisher = "Current Medicine Group",
number = "3",

}

TY - JOUR

T1 - Personalized Therapy of Hypertension

T2 - the Past and the Future

AU - Manunta, Paolo

AU - Ferrandi, Mara

AU - Cusi, Daniele

AU - Ferrari, Patrizia

AU - Staessen, Jan

AU - Bianchi, Giuseppe

PY - 2016/3/1

Y1 - 2016/3/1

N2 - During the past 20 years, the studies on genetics or pharmacogenomics of primary hypertension provided interesting results supporting the role of genetics, but no actionable finding ready to be translated into personalized medicine. Two types of approaches have been applied: a “hypothesis-driven” approach on the candidate genes, coding for proteins involved in the biochemical machinery underlying the regulation of BP, and an “unbiased hypothesis-free” approach with GWAS, based on the randomness principles of frequentist statistics. During the past 10–15 years, the application of the latter has overtaken the application of the former leading to an enlargement of the number of previously unknown candidate loci or genes but without any actionable result for the therapy of hypertension. In the present review, we summarize the results of our hypothesis-driven approach based on studies carried out in rats with genetic hypertension and in humans with essential hypertension at the pre-hypertensive and early hypertensive stages. These studies led to the identification of mutant adducin and endogenous ouabain as candidate genetic-molecular mechanisms in both species. Rostafuroxin has been developed for its ability to selectively correct Na+ pump abnormalities sustained by the two abovementioned mechanisms and to selectively reduce BP in rats and in humans carrying the gene variants underlying the mutant adducin and endogenous ouabain (EO) effects. A clinical trial is ongoing to substantiate these findings. Future studies should apply both the candidate gene and GWAS approaches to fully exploit the potential of genetics in optimizing the personalized therapy.

AB - During the past 20 years, the studies on genetics or pharmacogenomics of primary hypertension provided interesting results supporting the role of genetics, but no actionable finding ready to be translated into personalized medicine. Two types of approaches have been applied: a “hypothesis-driven” approach on the candidate genes, coding for proteins involved in the biochemical machinery underlying the regulation of BP, and an “unbiased hypothesis-free” approach with GWAS, based on the randomness principles of frequentist statistics. During the past 10–15 years, the application of the latter has overtaken the application of the former leading to an enlargement of the number of previously unknown candidate loci or genes but without any actionable result for the therapy of hypertension. In the present review, we summarize the results of our hypothesis-driven approach based on studies carried out in rats with genetic hypertension and in humans with essential hypertension at the pre-hypertensive and early hypertensive stages. These studies led to the identification of mutant adducin and endogenous ouabain as candidate genetic-molecular mechanisms in both species. Rostafuroxin has been developed for its ability to selectively correct Na+ pump abnormalities sustained by the two abovementioned mechanisms and to selectively reduce BP in rats and in humans carrying the gene variants underlying the mutant adducin and endogenous ouabain (EO) effects. A clinical trial is ongoing to substantiate these findings. Future studies should apply both the candidate gene and GWAS approaches to fully exploit the potential of genetics in optimizing the personalized therapy.

KW - Adducin

KW - Candidate gene

KW - Endogenous ouabain

KW - Genetics

KW - GWAS

KW - Hypertension

KW - Kidney cross-transplantation

KW - Personalized therapy

KW - Pharmacogenomics

KW - Rostafuroxin

UR - http://www.scopus.com/inward/record.url?scp=84959356955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959356955&partnerID=8YFLogxK

U2 - 10.1007/s11906-016-0632-y

DO - 10.1007/s11906-016-0632-y

M3 - Article

VL - 18

SP - 1

EP - 11

JO - Current Hypertension Reports

JF - Current Hypertension Reports

SN - 1522-6417

IS - 3

M1 - 24

ER -